At a glance
- Originator Daiichi Pharmaceutical
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 27 Dec 2000 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
- 03 Aug 1998 No-Development-Reported for Bacterial infections in Japan (Unknown route)
- 18 Apr 1995 Preclinical development for Bacterial infections in Japan (Unknown route)